Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh & Farideh Javid. (2023) Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert Review of Clinical Pharmacology 16:1, pages 49-59.
Read now
Read now
Eugene Han, Minyoung Lee, Yong-ho Lee, Hye Soon Kim, Byung-wan Lee, Bong-Soo Cha & Eun Seok Kang. (2020) Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity 13, pages 4113-4121.
Read now
Read now
Na Wang, Tao Yang, Jie Li & Xianfeng Zhang. (2019) Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes, Metabolic Syndrome and Obesity 12, pages 1513-1526.
Read now
Read now
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Makoto Ueno, Miyuki Matsukawa, Tomoko Yamakura, Kazuyo Sasaki, Mayumi Kimura & Hiroaki Iijima. (2018) Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 19:2, pages 83-91.
Read now
Read now
Takashi Kadowaki, Satsuki Muto, Yoshiumi Ouchi, Ryutaro Shimazaki & Yutaka Seino. (2017) Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opinion on Pharmacotherapy 18:18, pages 1903-1919.
Read now
Read now
Articles from other publishers (16)
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan & J. Chimakurthy. (2023) Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes. Journal of Endocrinological Investigation 46:5, pages 855-867.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Tatsuki Teranishi. (2022) Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan. Advances in Therapy 39:4, pages 1642-1658.
Crossref
Crossref
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min, Eun Jung Kyung, Yeo Kyeong Kim & Kwan Woo Lee. (2021) Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study. Diabetes Therapy 12:11, pages 2907-2920.
Crossref
Crossref
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Jin Yang, Qing Tian, Yuexin Tang, Arvind K. Shah, Ruya Zhang, Guojuan Chen, Ye Zhang, Swapnil Rajpathak & Tianpei Hong. (2020) Effect of Dipeptidyl Peptidase 4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Therapy 11:10, pages 2371-2382.
Crossref
Crossref
Sujoy Ghosh, Mangesh Tiwaskar, Rajiv Chawla, Shalini Jaggi, Arthur Asirvatham & Vijay Panikar. (2020) Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2). Diabetes Therapy 11:10, pages 2257-2268.
Crossref
Crossref
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki & Yuka Yamada. (2020) Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan. Advances in Therapy 37:5, pages 2477-2492.
Crossref
Crossref
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki, Miyuki Matsukawa & Yuka Yamada. (2019) Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan. Advances in Therapy 37:3, pages 1065-1086.
Crossref
Crossref
Eiichi Araki, Yuriko Unno, Yuko Tanaka, Wataru Sakamoto & Yuki Miyamoto. (2019) Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial. Advances in Therapy 36:10, pages 2697-2711.
Crossref
Crossref
Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima, Takahiro Matsui & Maki Gouda. (2019) The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs 79:7, pages 733-750.
Crossref
Crossref
Yonghyun Kim, Eun Seok Kang, Hak Chul Jang, Dong Jun Kim, Taekeun Oh, Eun Sook Kim, Nan-Hee Kim, Kyung Mook Choi, Sung-Rae Kim, JiYoung You, Se-Jin Kim & Moon-Kyu Lee. (2019) Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 21:3, pages 631-639.
Crossref
Crossref
Masakazu Haneda, Takashi Kadowaki, Hiroshi Ito, Kazuyo Sasaki, Sonoe Hiraide, Manabu Ishii, Miyuki Matsukawa & Makoto Ueno. (2018) Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance. Diabetes Therapy 9:3, pages 1083-1097.
Crossref
Crossref
Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito, Kazuyo Sasaki, Sonoe Hiraide, Miyuki Matsukawa & Makoto Ueno. (2018) Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients. Advances in Therapy 35:6, pages 817-831.
Crossref
Crossref
Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye & Jianming Wu. (2018) Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 9.
Crossref
Crossref
Takashi Kadowaki, Kazuyo Sasaki, Manabu Ishii, Miyuki Matsukawa & Yoshiteru Ushirogawa. (2018) Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies. Diabetes Therapy 9:2, pages 623-636.
Crossref
Crossref
Carolyn F. Deacon. (2018) A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism 20, pages 34-46.
Crossref
Crossref